Source disclosure: February 12, 2026
ROHTO PHARMACEUTICAL CO.,LTD. [4527.T]
TOKYO, Feb 18 (Pulse News Wire) – Rohto Pharmaceutical Co., Ltd. (4527.T) reported consolidated results for Q3 FY2026 (ending March 2026).
0% YoY). 6 billion (+5.1%). net profit attributable to shareholders was ¥28.3 billion (+14.3%).
3%. For the next fiscal year, the company forecasts 3%).
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
AI-translated content. 🟢 Confidence: High See terms •Financial results — FY2026/3 (consolidated)
| Metric | Current | YoY |
|---|---|---|
| Revenue | ¥253,071M | +12.0% |
| Operating profit | ¥33,575M | +5.1% |
| Net profit | ¥28,279M | +14.3% |
Next period forecast
Revenue
¥340,500M
+10.3%Op. profit
¥40,500M
+5.9%Net profit
¥33,000M
+7.0%Source: TDNet filing · Figures in millions of yen
💬 Help us improve translation quality
Notice any errors in this article? Let us know with one click.